Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Advanced prostate cancer management benefits from PARP inhibition, but modest patient outcomes and frequent disease progression necessitate improved strategies.
• Understanding tumor cell responses to PARP inhibitors (PARPi) is crucial for developing novel approaches to enhance treatment efficacy and duration.

Purpose of the Study:

• To investigate the time-dependent cellular responses of advanced prostate cancer to PARP inhibition.
• To identify potential therapeutic targets to overcome resistance and improve PARPi efficacy.

Main Methods:

• Cell viability assays, microscopy, and RNA sequencing were employed to characterize PARPi response and transcriptomic changes.
• Western blots, flow cytometry, and additional assays validated RNA sequencing findings and tested therapeutic strategies.

Main Results:

• Short-term PARPi treatment activates ATM, DNA damage response, and cell cycle checkpoints; co-targeting ATM enhances tumor cell death.
• Long-term PARPi exposure induces SLUG-dependent epithelial-mesenchymal transition (EMT) and alters fatty acid metabolism, presenting potential therapeutic targets.
• Time-dependent cellular responses to PARPi offer opportunities for targeted interventions.

Conclusions:

• This study elucidates short- and long-term cellular responses to PARPi in prostate cancer.
• Findings provide a foundation for developing strategies to maximize the clinical utility of PARP inhibition in prostate cancer management.